News Quantified

OKYO – okyo pharma limited - ordinary shares (US:NASDAQ)

OKYO Pharma to present first-in-human urcosimod data at ARVO 2026 [Yahoo! Finance]

2/23

11:00 am

okyo

Low

OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress

OKYO Pharma (NASDAQ:OKYO) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.

OKYO Pharma (NASDAQ:OKYO) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.

OKYO Pharma has analysts bullish as FDA endorses Phase 2b/3 trial in neuropathic corneal pain [Yahoo! Finance]

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}